Paladin’s AI-enhanced autonomous drones help public safety agencies, such as police and fire departments, respond to 911 calls. Photo via paladindrones.io

Houston-based Paladin, whose remotely controlled drones help first responders react quickly to emergencies, has collected $5.2 million in seed funding.

Gradient, a seed fund that backs AI-oriented startups, led the round. Also participating were Toyota Ventures, the early-stage VC arm of Japanese automaker Toyota; venture capital firm Khosla Ventures; and VC fund 1517.

“We believe Paladin will drive meaningful change in public safety and redefine how communities are served,” Gradient said in an announcement about the seed round.

In 2019, Paladin received $1.3 million in seed funding from Khosla Ventures and Gmail creator Paul Buchheit, a group partner at Y Combinator. In 2018, the year it was co-founded by Divyaditya Shrivastava and Trevor Pennypacker, Paladin graduated from Y Combinator’s three-month boot camp.

Paladin’s AI-enhanced autonomous drones help public safety agencies, such as police and fire departments, respond to 911 calls. These drones provide aerial views of emergency scenes in an effort to decrease response times, improve “situational awareness,” and save lives, according to a Gradient blog post.

Among the agencies that have tried out Paladin’s technology is the Houston area’s Memorial Villages Police Department. The department participated in a three-month Paladin pilot project in 2019.

"(This is) one of the first departments in the country to be testing this technology," Shrivastava told InnovationMap in 2019. "We're very limited in the area that we cover, and that's just because we're taking baby steps and going as carefully and deliberately as possible."

Gradient says more than 12,000 drone missions have been performed using Paladin’s hardware and software platform. Agencies that have adopted the platform report average response times under 90 seconds. Furthermore, the technology has allowed them to resolve nearly one-third of 911 calls without dispatching first responders.

“Paladin keeps innovating, recently launching Payload Drop, a groundbreaking feature that enables drones to deliver lifesaving equipment — such as Narcan, life vests, and AEDs — directly to emergency scenes,” says Gradient.

On its website, Paladin says it envisions autonomous drones responding to every 911 call in the U.S. by 2027.

“The information is paramount, the technology exists and is rapidly improving, and the need is there. We want to help,” Paladin proclaims.

Paladin Drones wants eyes in the skies within 30 seconds of an emergency call. Getty Images

Houston drone company creating the next generation of first responders

To the rescue

When 911 is called, first responders usually arrive at the scene around three or four minutes after the call's placed. But Houston-based Paladin Drones wants to have eyes on the ground ­— or eyes in the sky — within the first 30 seconds.

The company's mission is simple: to outfit public agencies and first-responders with drones that can be autonomously deployed to the site of an emergency. Equipped with thermal sensors and flying around 200 feet high, the drones can give police and firefighters near-instantaneous information on a situation underway.

At the beginning of April, Paladin Drones began working with the Memorial Villages Police Department to respond to incidents in Memorial Villages, Hunter's Creek, Piney Point Village, and Bunker Hill.

"(This is) one of the first departments in the country to be testing this technology," says Paladin Drones co-founder Divyaditya Shrivastava. "We're very limited in the area that we cover, and that's just because we're taking baby steps and going as carefully and deliberately as possible."

Paladin Drones was co-founded by Shrivastava and Trevor Pennypacker. In 2018, the company went through a three-month boot camp at Y Combinator, a California-based incubator that's churned out Dropbox, AirBNB, Instacart and more. Through Y Combinator, Paladin Drones was connected with venture capital investors in Houston.

The company's drones capture critical information, such as a vehicle's color and body type, a suspect's clothing, or the direction a suspect fled the scene. And since roughly 70 percent of 911 calls involve witnesses or passerby giving inaccurate information about the emergency's location, these drones will be able to pinpoint the exact location of an emergency, further aiding the arrival of first responders.

"We're working on tracking technology to give the drones the capability to auto-follow (suspects)," Shrivastava says.

Paladin Drones is looking to hire a handful of employees in the coming months, Shrivastava says. He declined to disclose any information on the company's funding plans, but said it's still involved with Y Combinator in California.

Shrivastava began developing Paladin Drones when he was finishing high school in Ohio. The summer before his senior year, a friend's house burned down. While nobody was injured in the fire, the home was destroyed, and Shrivastava spoke with the local firefighters. Tragically, the 911 call that alerted firefighters of the emergency was one of the 70 percent of calls that involved inaccurate location information.

"If they'd known the exact location, the house would've been saved," Shrivastava says. "A fire doubles every 30 seconds."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”